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Insulin-like growth factors (lOF)-1 and -II induce a variety of cellular outcomes 
including cell proliferation, differentiation, cell migration and protection from 
apoptosis. IOF-I and IOF-II share a high degree of structural similarity reflecting their 
high level of sequence similarity. Despite this both IOP-l and IOF-II exhibit different 
binding affinities to almost all proteins with which they both interact. To date few 
studies have investigated the structural basis whereby IOP-l and lOP-II bind with 
different affmities to the type-J IOF receptor (lOF-IR), insulin receptor (IR) isoforms, 
type-2 lOP receptor (IOP-2R) and IOF binding proteins (lOPBPs). The major 
objective of this thesis is to investigate the molecular basis for the unique receptor and 
binding protein binding properties of IOF-I and lOF-II 
To address the question of what parts ofiOF-1 and IOF-II confer their unique 
receptor and binding protein binding affinities, chimeras of IOF-I and IOF-II were 
engineered where their C and D domains were exchanged either singly or together. 
" 
These are the first ever whole domain chimeras of IOP-I and IOF-II. Recently the 
alternatively spliced isoform of the insulin receptor lacking 12 amino acids encoded by 
exon 11 (IR-A) has been shown to be overexpressed in foetal and cancer tissues and 
bind lOP-II but not IOF-l with high affinity. Binding analysis of the engineered 
chimeras to the lR-A showed that the C and D domains of IOF-I1 allow high affinity 
binding whereas the same domains of IOF-l preclude high affinity binding to the IR-A. 
The C and D domains also regulate the differential interaction of IOF-l and IOF-I1 
with the insulin receptor isoform containing the amino acids encoded by exon 11 
(IR-B). The C domain of IOF-II, in the background of IOF-II or IOF-I, also allows 
potent induction of phosphorylation of various tyrosine residues in the intracellular 13 
subunits of the lR-A and lR-B, whereas the same domain of lGF-I in the background 
of lGF-II did not. In addition this same domain also is the molecular basis for the 
differential ability of IGF-II and IGF-I to phosphorylate IRS- l and activate PKBI Akt. 
Furthennore, the differential ability of IGF-II and lGF-l to induce cell survival and 
promote cell migration via the IR-A is due to their C domains. 
The lGF-IR binds lGF-I with a 3-5 fold higher affinity than IGF-II. Here in 
this thesis the differential affinity of lGF-I and IGF-II for the lGF-1 R is shown to be in 
a large part due to their C and D domains. 
The lGF-2R is a receptor that does not contain any intrinsic signaling activity 
and in the context of the IGF system appears to regulate the concentration of IGF-II. 
lGF-2R binds lGF-II with high affinity but binds lGF-I with very low affinity. 
Reported here is the novel identification of the IGF-II C domain as an important 
contributor for wildtype IGF-2R binding. lGFBPs act to both potentiate and inhibit the 
cellular actions of the lGFs. Almost all lGFBPs bind lGF-I and lGF-II with different 
affinities, particularly IGFBP-6 which has a 10-60 fold higher affinity for lGF-II 
compared to lGF-I. Binding analysis of IGF chimeras to IGFBP-l, -2, -3 revealed that 
, 
the C and D domains of the IGFs do not regulate any IGFBP affinity difference, 
however the IGF-II C domain may play a small role in binding to IGFBP-6. 
Recently a patient exhibiting mental retardation, short stature and gondal 
dysfunction was shown to be homozygous for a mutation in his IGF-l gene resulting in 
a protein with a methionine instead of a valine at position 44. Here in this thesis the 
biochemical characterization of this mutant is reported. This mutation causes almost a 
90-fold reduction in IGF-IR binding affinity, while completely abrogating binding to 
either lR isoform. Interestingly binding to IGFBP-2, ·3 and -{) is unaffected. In 
addition, NMR analysis showed only small perturbations in the structure localized 
around the site of the mutation. 
In conclusion this thesis has contributed to the understanding of ligand receptor 
interactions of the insulinllGF system. 
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